Literature DB >> 22963983

Enhanced CD36 expression changes the role of Nrf2 activation from anti-atherogenic to pro-atherogenic in apoE-deficient mice.

Hirotaka Sawada1, Yoshiro Saito, Noriko Noguchi.   

Abstract

Oxidative stress has been implicated as a causative factor of atherosclerosis. Defense systems against oxidative stress are maintained by radical scavenging antioxidants and/or by regulating the expression of antioxidant genes by activating oxidative stress-sensitive transcription factor: nuclear factor (erythroid-derived 2)-like 2 (Nrf2). We investigated the anti-atherogenic effects of three synthesized compounds (shogaol A: radical scavenging antioxidant activity; shogaol N: Nrf2-activating activity; shogaol N + A: both activities) and curcumin (both activities) in apolipoprotein E (apoE)-deficient mice. We expected compounds with both activities to have additive or synergistic anti-atherogenic effects; however, atherosclerosis was exacerbated significantly by curcumin and slightly by shogaol N + A. Shogaol A, shogaol N, and shogaol N + A showed no significant effect on atherosclerosis development. Immunohistochemical analysis of the aorta revealed that expression of CD36, an Nrf2-regulated gene, was strongly induced by treatment with curcumin. The total antioxidant capacity of plasma collected from mice administered the three compounds was evaluated using a hydrophilic probe, pyranine. Shogaol N or shogaol N + A significantly enhanced the antioxidant capacity of plasma, whereas shogaol A and curcumin did not show this activity. The concentrations of the three shogaol derivatives in plasma were similar (approximately 100 nM), while that of curcumin was much lower. These results suggest that plasma antioxidant capacity is maintained at high levels via Nrf2 activation and that CD36 expression enhances atherosclerosis development.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963983     DOI: 10.1016/j.atherosclerosis.2012.08.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  CD36 mediates endothelial dysfunction downstream of circulating factors induced by O3 exposure.

Authors:  Sarah Robertson; Elizabeth S Colombo; Selita N Lucas; Pamela R Hall; Maria Febbraio; Michael L Paffett; Matthew J Campen
Journal:  Toxicol Sci       Date:  2013-05-06       Impact factor: 4.849

2.  MMP-9-Dependent Serum-Borne Bioactivity Caused by Multiwalled Carbon Nanotube Exposure Induces Vascular Dysfunction via the CD36 Scavenger Receptor.

Authors:  Mario Aragon; Aaron Erdely; Lindsey Bishop; Rebecca Salmen; John Weaver; Jim Liu; Pamela Hall; Tracy Eye; Vamsi Kodali; Patti Zeidler-Erdely; Jillian E Stafflinger; Andrew K Ottens; Matthew J Campen
Journal:  Toxicol Sci       Date:  2016-01-21       Impact factor: 4.849

3.  Lipoicmethylenedioxyphenol Reduces Experimental Atherosclerosis through Activation of Nrf2 Signaling.

Authors:  Zhekang Ying; Minjie Chen; Xiaoyun Xie; Xiaoke Wang; Nisharahmed Kherada; Rajagopal Desikan; Georgeta Mihai; Patrick Burns; Qinghua Sun; Sanjay Rajagopalan
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

4.  Efficacy of Curcumin on Aortic Atherosclerosis: A Systematic Review and Meta-Analysis in Mouse Studies and Insights into Possible Mechanisms.

Authors:  Ke Lin; Huaijun Chen; Xiaojun Chen; Jinfu Qian; Shushi Huang; Weijian Huang
Journal:  Oxid Med Cell Longev       Date:  2020-01-09       Impact factor: 6.543

Review 5.  New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis.

Authors:  Ting Yuan; Ting Yang; Huan Chen; Danli Fu; Yangyang Hu; Jing Wang; Qing Yuan; Hong Yu; Wenfeng Xu; Xiang Xie
Journal:  Redox Biol       Date:  2018-10-19       Impact factor: 11.799

Review 6.  Role of Nrf2 and Its Activators in Cardiocerebral Vascular Disease.

Authors:  Liangkai Cheng; Hong Zhang; Fang Wu; Zhongqiu Liu; Yuanyuan Cheng; Caiyan Wang
Journal:  Oxid Med Cell Longev       Date:  2020-08-05       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.